Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
39 participants
OBSERVATIONAL
2015-02-06
2020-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
\- Maculopathies are eye conditions that affect the center of the retina. Retina health depends on the retinal pigment epithelium (RPE), a layer behind the retina. A new test may measure the health of the central retina and RPE.
Objective:
\- To use the focal electro-oculogram (EOG) test to understand how the central retina and RPE are affected in maculopathies.
Eligibility:
* People at least 10 years old with a maculopathy.
* Healthy volunteers with visual acuity of 20/20 or better in at least one eye.
Design:
* Participants will be screened with medical and eye history and an eye exam. Pictures will be taken of the eyes.
* Their eyes may be dilated.
* They may have a field test. They will look into a lens and press a button when they see a light. First, they may sit in the dark for 40 minutes.
* Participants will have 1-7 visits over 18 months.
* Their vision will be tested and eye pressure measured.
* Their pupils will be dilated with eye drops and researchers may take pictures of the retina and the inside of the eye, and measure the thickness of the retina.
* Participants will have an electro-oculogram. They will look at a 2 LED lights and follow them back and forth for 10 seconds once per minute. Participants will be in darkness for 15 minutes and in light for 20 minutes. One skin electrode will be placed on the nose and one next to the eye.
* Participants with maculopathy will also have:
* Field test.
* Electroretinogram. Participants will get numbing eye drops and special contact lenses. A small metal electrode will be taped to the forehead. Participants will watch flashing lights and try not to blink. First, they may sit in the dark for 40 minutes.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The objective of this protocol is to investigate the local response of the retinal pigment epithelium (RPE) across the posterior pole of the eye by recording the focal electrooculogram (EOG) in participants with macular disease.
STUDY POPULATION:
Up to 50 healthy volunteers and 80 participants, age 10 or older, with macular disorders affecting the retina/retinal pigment epithelium complex. Examples of such macular disorders include Stargardt s disease and age-related macular degeneration (AMD).
DESIGN:
This single-center, observational, case-control study will be comprised of three related aims. The first aim is focused on developing the focal EOG method which will require parameter optimization. The second aim is focused on establishing the normal range and variability of the focal EOG in normal volunteers. The third aim is to examine the focal EOG in participants with macular disease.
OUTCOME MEASURES:
The primary outcome for this study is to develop a method for recording the focal EOG. The secondary outcome will be to establish the normal range for the focal EOG and determine the inter-session and intra-session variabilities of this test. Exploratory outcomes include: 1) to examine the focal EOG in participants with macular diseases and 2) determine the inter-session and intra-session variabilities of this test in participants with macular diseases.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Affected
Participants with macular disease
No interventions assigned to this group
Unaffected
Healthy volunteers
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Participant (or legal guardian) must understand and sign the protocol s informed consent document.
3. Participant must be able to cooperate with the testing required for this study.
4. For Participants with macular disease only:
1. Participant must have macular disease, defined as evidence of loss of centrally mediated retinal dysfunction and/or degeneration as established by standard clinical methods including perimetry, ERG and imaging.
2. Participant must have a measurable visual acuity.
5. For Healthy Volunteers only:
1. Participant must have visual acuity of 20/20 or better in at least one eye.
Exclusion Criteria
10 Years
100 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Eye Institute (NEI)
NIH
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Brett G Jeffrey, Ph.D.
Role: PRINCIPAL_INVESTIGATOR
National Eye Institute (NEI)
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
National Institutes of Health Clinical Center
Bethesda, Maryland, United States
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
NIH Clinical Center Detailed Web Page
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
14-EI-0171
Identifier Type: -
Identifier Source: secondary_id
140171
Identifier Type: -
Identifier Source: org_study_id